Therefore, the use of Sibilin, Zerumbone, or curcumin/epigallocatechin notably reduced the population of CD44+ tumor cells (breast cancer, pancreatic cancer, and prostate cancer), suggesting a novel approach for the treatment of sarcomas. This evidence concerns the gene CD44 and neoplasm.